Uj, sugárzásmentes csontvelö-transzplantációs kondicionáló kezelés dibróm-mannitollal krónikus myeloid leukaemiában.

Translated title of the contribution: A new radiation-free conditioning in bone marrow transplantation and dibromo-mannitol therapy in chronic myeloid leukemia

E. Kelemen, R. Dénes, A. Barta, T. Masszi, P. Reményi, K. Pálóczi, A. Bátai, E. Torbágyo, A. Sipos, L. Lengyel, K. Jakab, E. Gyódi, M. Réti, J. Földi, P. Páldi-Haris, A. Manuel, S. Fekete, J. Török, I. Hoffer, J. JakabG. Váradi, G. Petrányi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A new, radiation-free, conditioning protocol, containing the original Hungarian mitobronitol (DBM) (DBM/ cytosine arabinoside/cyclosphosphamide) has been applied to 36 chronic myeloid leukemia (CML) patients followed by bone marrow transplantation (BMT) from HLA identical sibling donors between 1990-1997. In spite of some prognostically disadvantageous factors (half of them were above 40 years, 10 out of 36 patients were in accelerated phase, the disease history was longer than 2 years in average) the overall survival (30/36) and the leukemia free survival rate (26/36) were in accordance with the best international results. Transplantation-related toxicity was remarkably reduced in comparison to bone marrow transplantation performed by total body irradiation/cyclophosphamide (TBI/Cy) or busulphan/cyclophosphamide (Bu/Cy) conditioning protocols. Acute graft versus host disease was present in lower percentage (9/36) and the number of serious cases was only 2/36. Chronic GVH disease, generally known to be associated with antileukemic effect (GVL), occurred in 25 of cases. Early haematological relapse among the 34 patients with functioning graft occurred in 6 patients which rate is slightly higher than reported after TBI/Cy or Bu/Cy conditioning treatment. There was no relapse among patients transplanted within one year post-diagnosis and patients having CML with accelerated phase. The leukemia free post-transplant period was in association with the chronic GVH disease and full chimeric state.

Original languageHungarian
JournalOrvosi Hetilap
Volume139
Issue number34
Publication statusPublished - Aug 23 1998

Fingerprint

Mannitol
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Radiation
Cyclophosphamide
Busulfan
Whole-Body Irradiation
Mitobronitol
Leukemia, Myeloid, Accelerated Phase
Leukemia
Chronic Disease
Therapeutics
Transplants
Recurrence
Cytarabine
Graft vs Host Disease
Conditioning (Psychology)
Siblings
Survival Rate
Transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Uj, sugárzásmentes csontvelö-transzplantációs kondicionáló kezelés dibróm-mannitollal krónikus myeloid leukaemiában. / Kelemen, E.; Dénes, R.; Barta, A.; Masszi, T.; Reményi, P.; Pálóczi, K.; Bátai, A.; Torbágyo, E.; Sipos, A.; Lengyel, L.; Jakab, K.; Gyódi, E.; Réti, M.; Földi, J.; Páldi-Haris, P.; Manuel, A.; Fekete, S.; Török, J.; Hoffer, I.; Jakab, J.; Váradi, G.; Petrányi, G.

In: Orvosi Hetilap, Vol. 139, No. 34, 23.08.1998.

Research output: Contribution to journalArticle

Kelemen, E, Dénes, R, Barta, A, Masszi, T, Reményi, P, Pálóczi, K, Bátai, A, Torbágyo, E, Sipos, A, Lengyel, L, Jakab, K, Gyódi, E, Réti, M, Földi, J, Páldi-Haris, P, Manuel, A, Fekete, S, Török, J, Hoffer, I, Jakab, J, Váradi, G & Petrányi, G 1998, 'Uj, sugárzásmentes csontvelö-transzplantációs kondicionáló kezelés dibróm-mannitollal krónikus myeloid leukaemiában.', Orvosi Hetilap, vol. 139, no. 34.
Kelemen, E. ; Dénes, R. ; Barta, A. ; Masszi, T. ; Reményi, P. ; Pálóczi, K. ; Bátai, A. ; Torbágyo, E. ; Sipos, A. ; Lengyel, L. ; Jakab, K. ; Gyódi, E. ; Réti, M. ; Földi, J. ; Páldi-Haris, P. ; Manuel, A. ; Fekete, S. ; Török, J. ; Hoffer, I. ; Jakab, J. ; Váradi, G. ; Petrányi, G. / Uj, sugárzásmentes csontvelö-transzplantációs kondicionáló kezelés dibróm-mannitollal krónikus myeloid leukaemiában. In: Orvosi Hetilap. 1998 ; Vol. 139, No. 34.
@article{e44ab3056d364980a84ecf0feb6228ca,
title = "Uj, sug{\'a}rz{\'a}smentes csontvel{\"o}-transzplant{\'a}ci{\'o}s kondicion{\'a}l{\'o} kezel{\'e}s dibr{\'o}m-mannitollal kr{\'o}nikus myeloid leukaemi{\'a}ban.",
abstract = "A new, radiation-free, conditioning protocol, containing the original Hungarian mitobronitol (DBM) (DBM/ cytosine arabinoside/cyclosphosphamide) has been applied to 36 chronic myeloid leukemia (CML) patients followed by bone marrow transplantation (BMT) from HLA identical sibling donors between 1990-1997. In spite of some prognostically disadvantageous factors (half of them were above 40 years, 10 out of 36 patients were in accelerated phase, the disease history was longer than 2 years in average) the overall survival (30/36) and the leukemia free survival rate (26/36) were in accordance with the best international results. Transplantation-related toxicity was remarkably reduced in comparison to bone marrow transplantation performed by total body irradiation/cyclophosphamide (TBI/Cy) or busulphan/cyclophosphamide (Bu/Cy) conditioning protocols. Acute graft versus host disease was present in lower percentage (9/36) and the number of serious cases was only 2/36. Chronic GVH disease, generally known to be associated with antileukemic effect (GVL), occurred in 25 of cases. Early haematological relapse among the 34 patients with functioning graft occurred in 6 patients which rate is slightly higher than reported after TBI/Cy or Bu/Cy conditioning treatment. There was no relapse among patients transplanted within one year post-diagnosis and patients having CML with accelerated phase. The leukemia free post-transplant period was in association with the chronic GVH disease and full chimeric state.",
author = "E. Kelemen and R. D{\'e}nes and A. Barta and T. Masszi and P. Rem{\'e}nyi and K. P{\'a}l{\'o}czi and A. B{\'a}tai and E. Torb{\'a}gyo and A. Sipos and L. Lengyel and K. Jakab and E. Gy{\'o}di and M. R{\'e}ti and J. F{\"o}ldi and P. P{\'a}ldi-Haris and A. Manuel and S. Fekete and J. T{\"o}r{\"o}k and I. Hoffer and J. Jakab and G. V{\'a}radi and G. Petr{\'a}nyi",
year = "1998",
month = "8",
day = "23",
language = "Hungarian",
volume = "139",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "34",

}

TY - JOUR

T1 - Uj, sugárzásmentes csontvelö-transzplantációs kondicionáló kezelés dibróm-mannitollal krónikus myeloid leukaemiában.

AU - Kelemen, E.

AU - Dénes, R.

AU - Barta, A.

AU - Masszi, T.

AU - Reményi, P.

AU - Pálóczi, K.

AU - Bátai, A.

AU - Torbágyo, E.

AU - Sipos, A.

AU - Lengyel, L.

AU - Jakab, K.

AU - Gyódi, E.

AU - Réti, M.

AU - Földi, J.

AU - Páldi-Haris, P.

AU - Manuel, A.

AU - Fekete, S.

AU - Török, J.

AU - Hoffer, I.

AU - Jakab, J.

AU - Váradi, G.

AU - Petrányi, G.

PY - 1998/8/23

Y1 - 1998/8/23

N2 - A new, radiation-free, conditioning protocol, containing the original Hungarian mitobronitol (DBM) (DBM/ cytosine arabinoside/cyclosphosphamide) has been applied to 36 chronic myeloid leukemia (CML) patients followed by bone marrow transplantation (BMT) from HLA identical sibling donors between 1990-1997. In spite of some prognostically disadvantageous factors (half of them were above 40 years, 10 out of 36 patients were in accelerated phase, the disease history was longer than 2 years in average) the overall survival (30/36) and the leukemia free survival rate (26/36) were in accordance with the best international results. Transplantation-related toxicity was remarkably reduced in comparison to bone marrow transplantation performed by total body irradiation/cyclophosphamide (TBI/Cy) or busulphan/cyclophosphamide (Bu/Cy) conditioning protocols. Acute graft versus host disease was present in lower percentage (9/36) and the number of serious cases was only 2/36. Chronic GVH disease, generally known to be associated with antileukemic effect (GVL), occurred in 25 of cases. Early haematological relapse among the 34 patients with functioning graft occurred in 6 patients which rate is slightly higher than reported after TBI/Cy or Bu/Cy conditioning treatment. There was no relapse among patients transplanted within one year post-diagnosis and patients having CML with accelerated phase. The leukemia free post-transplant period was in association with the chronic GVH disease and full chimeric state.

AB - A new, radiation-free, conditioning protocol, containing the original Hungarian mitobronitol (DBM) (DBM/ cytosine arabinoside/cyclosphosphamide) has been applied to 36 chronic myeloid leukemia (CML) patients followed by bone marrow transplantation (BMT) from HLA identical sibling donors between 1990-1997. In spite of some prognostically disadvantageous factors (half of them were above 40 years, 10 out of 36 patients were in accelerated phase, the disease history was longer than 2 years in average) the overall survival (30/36) and the leukemia free survival rate (26/36) were in accordance with the best international results. Transplantation-related toxicity was remarkably reduced in comparison to bone marrow transplantation performed by total body irradiation/cyclophosphamide (TBI/Cy) or busulphan/cyclophosphamide (Bu/Cy) conditioning protocols. Acute graft versus host disease was present in lower percentage (9/36) and the number of serious cases was only 2/36. Chronic GVH disease, generally known to be associated with antileukemic effect (GVL), occurred in 25 of cases. Early haematological relapse among the 34 patients with functioning graft occurred in 6 patients which rate is slightly higher than reported after TBI/Cy or Bu/Cy conditioning treatment. There was no relapse among patients transplanted within one year post-diagnosis and patients having CML with accelerated phase. The leukemia free post-transplant period was in association with the chronic GVH disease and full chimeric state.

UR - http://www.scopus.com/inward/record.url?scp=0032560864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032560864&partnerID=8YFLogxK

M3 - Article

C2 - 9745304

AN - SCOPUS:0032560864

VL - 139

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 34

ER -